Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Infinity Pharmaceuti (INFI)

Infinity Pharmaceuti (INFI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Infinity (INFI) Q3 Loss Wider Than Expected, IPI-549 in Focus

Infinity's (INFI) wider-than-estimated loss in Q3 displeases investors. Revenues too fall short of the mark.

RHHBY : 38.5700 (+0.36%)
BMY : 59.95 (+0.79%)
INFI : 1.24 (-0.80%)
RCUS : 8.22 (+5.52%)
Infinity (INFI) Q3 Loss Wider Than Expected, IPI-549 in Focus

Infinity's (INFI) wider-than-estimated loss in Q3 displeases investors. Revenues too fall short of the mark.

RHHBY : 38.5700 (+0.36%)
BMY : 59.95 (+0.79%)
INFI : 1.24 (-0.80%)
RCUS : 8.22 (+5.52%)
Infinity Pharmaceuticals (INFI) Reports Q3 Loss, Lags Revenue Estimates

Infinity (INFI) delivered earnings and revenue surprises of -11.11% and -59.65%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

INFI : 1.24 (-0.80%)
Infinity: 3Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Infinity Pharmaceuticals Inc. (INFI) on Wednesday reported a third-quarter loss of $11.4 million, after reporting a profit in the same period a year earlier.

INFI : 1.24 (-0.80%)
Infinity Pharmaceuticals Provides Company Update and Third Quarter 2019 Financial Results

-- MARIO-3 Enrollment Completion and Data Presentation Expected in 2020 --

INFI : 1.24 (-0.80%)
Breast Cancer Awareness Month Arrives With New Teamwork From Biotech Developers on the Way

USA News Group - As October rolled in to welcome the 35th annual Breast Cancer Awareness Month, hope remains alive as new drugs continue to develop from the biotech sector. These include the smaller cap...

PFE : 38.29 (+0.68%)
MRK : 88.85 (+0.11%)
RHHBY : 38.5700 (+0.36%)
INFI : 1.24 (-0.80%)
ONCY : 1.14 (unch)
ONC.TO : 1.53 (+3.38%)
Infinity Announces the Date of Its Third Quarter 2019 Financial Results Conference Call and Webcast

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will host a conference call on Wednesday, October 30, 2019 at 4:30 p.m. ET to review its third quarter 2019 financial results and provide an update on the...

INFI : 1.24 (-0.80%)
Verastem's (VSTM) Copiktra Gets Orphan Drug Designation

Verastem's (VSTM) Copiktra gets orphan drug designation from the FDA for use in the treatment of T-Cell lymphoma.

SNY : 46.03 (-0.11%)
MRK : 88.85 (+0.11%)
VSTM : 1.32 (+5.60%)
INFI : 1.24 (-0.80%)
Infinity's (INFI) IPI-549 in Focus in a Crowded Cancer Space

Infinity (INFI) is currently focusing on the development of its lead immuno-oncology candidate IPI-549, an orally administered treatment that selectively inhibits phosphoinositide-3 kinase (PI3K)-gamma....

BMY : 59.95 (+0.79%)
RHHBY : 38.5700 (+0.36%)
INFI : 1.24 (-0.80%)
RCUS : 8.22 (+5.52%)
Infinity Initiates 2 Studies for Lead Candidate IPI-549

Infinity (INFI) initiates two studies for IPI-549 -- a first-in-class, oral immuno-oncology product candidate.

BMY : 59.95 (+0.79%)
RHHBY : 38.5700 (+0.36%)
INFI : 1.24 (-0.80%)
RCUS : 8.22 (+5.52%)
Infinity Pharmaceuticals Announces the Initiation of Two Clinical Trials Evaluating IPI-549 in Novel Triple Combination Therapies for the Treatment of Solid Tumors

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced the initiation of two clinical trials for IPI-549, a first-in-class, oral immuno-oncology product candidate targeting immune-suppressive tumor-associated...

INFI : 1.24 (-0.80%)
Infinity to Present at Two Upcoming Conferences in September

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing IPI-549, a potentially first-in-class immuno-oncology product candidate that selectively inhibits phosphoinositide-3-kinase...

WFC : 54.37 (+2.14%)
INFI : 1.24 (-0.80%)
Infinity Pharmaceuticals Announces Transition of Samuel Agresta, M.D., from Chief Medical Officer to Board of Directors

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that Samuel Agresta, M.D., will transition from his role as Chief Medical Officer to Infinity's Board of Directors and Research and Development...

INFI : 1.24 (-0.80%)
Infinity Pharmaceuticals (INFI) Reports Q2 Loss, Lags Revenue Estimates

Infinity (INFI) delivered earnings and revenue surprises of -20.00% and -90.12%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

INFI : 1.24 (-0.80%)
Infinity: 2Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Infinity Pharmaceuticals Inc. (INFI) on Tuesday reported a loss of $10.5 million in its second quarter.

INFI : 1.24 (-0.80%)
Infinity Pharmaceuticals Provides Company Update and Second Quarter 2019 Financial Results

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its second quarter 2019 financial results and provided an update on the company, including its progress with IPI-549, a first-in-class oral...

INFI : 1.24 (-0.80%)
Infinity Announces The Date Of Its Second Quarter 2019 Financial Results Conference Call And Webcast

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will host a conference call on Tuesday, July 30, 2019 at 8:00 a.m. ET to review its second quarter 2019 financial results and provide an update on the company....

INFI : 1.24 (-0.80%)
Verastem Up on Positive Data From Early-Stage Copiktra Study

Verastem (VSTM) presents encouraging data from an early-stage study evaluating its recently approved drug, Copiktra, for treating peripheral T-cell lymphoma.

MRK : 88.85 (+0.11%)
VSTM : 1.32 (+5.60%)
INFI : 1.24 (-0.80%)
TAK : 20.26 (-0.88%)
Infinity (INFI) Up 6% Since Last Earnings Report: Can It Continue?

Infinity (INFI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

INFI : 1.24 (-0.80%)
Infinity Pharmaceuticals To Present At B. Riley FBR Institutional Investor Conference

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced today that Adelene Perkins, Infinity Pharmaceutical's Chief Executive Officer, will present at the B. Riley FBR Institutional Investor Conference...

INFI : 1.24 (-0.80%)

Van Meerten Stock Picks

The 5 Best Large Caps
I wanted to find which Large Caps had the best momentum so I used Barchart to sort the S&P 500 Large Cap Index first by the highest technical buy signals, then by the most frequent number of new highs in the last month.
CCI +0.46 , AIZ +1.17 , SBAC +0.55 , SO -0.62 , WELL -0.29
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar